First Republic offers a comprehensive set of banking services, connections and guidance to support the growth of your business at every stage. We are committed to fast response and ease of use through our dedicated life sciences team, based in innovation hubs across the U.S. Our Life Science Toolkit offers you discounts on an additional suite of mission-critical services to address many of your immediate operational needs. Learn more. First Republic Bank is a member of the FDIC
Life Science companies need more from a bank than just accounts and transactions. The right banking partner brings a mix of excellent service, industry expertise, and the ability to help companies grow. Join Nishta Rao of First Republic Bank to hear what companies should be looking for in a sound banking partner.
Nishta Rao, Managing Director, Life Science, First Republic Bank
Nishta is currently Managing Director at First Republic Bank where she is responsible for the growth and expansion of the Bank’s Life Science vertical. Prior to this, Nishta was Managing Director, BioLabs@NYULangone where she supported the translation of technologies into commercially viable products and therapies. In addition Nishta has also launched and led Princeton Innovation Center BioLabs (PICb). Nishta served as Senior Director of Scientific Operations at Kadmon, a biotech startup based in New York City that focuses on discovery, development, and commercialization of small molecules and biologics. Nishta, a molecular biologist by training, has scientific experience both in academia and industry. She has worked at Mt. Sinai Innovation Partners, the technology transfer office at Mt. Sinai as a Business Development Analyst evaluating technologies and developing partnerships aimed towards commercialization of new technologies. Nishta also serves as a mentor to several startup companies in the Life Science and Healthcare space.
Pepper Landson, Co-Founder & CEO, Praetego
Pepper Landson is an accomplished healthcare executive with 30 years of experience in research and development, positively impacting over 100 drug development programs. Her tenacity fuels innovation and her talents energize successful teams. In the last decade, she has focused exclusively on novel therapeutics to address chronic diseases of aging.
Combining her skills in business development and operations with an extensive drug development background, she founded two companies, and was a key figure in an IPO. Gifted at motivating talent to exceed expectations, Ms. Landson recruited a world class advisory board for her current company, Praetego, a preclinical stage pharmaceutical company committed to improving health outcomes in neurodegenerative diseases.
Since founding Praetego, she has successfully led funding efforts in both public and private sectors. She is driving the expansion of Praetego’s patent portfolio and development pipeline. Using her power for good, she leads a company aiming to satisfy investors AND patients. Through Praetego she will revolutionize how we can extend healthspan.
SUMAN LAL, Founder, Zero-to-One
SUMAN LAL is an entrepreneur whose interests and expertise is in technology commercialization. He is currently founder and CEO of Zero-to-One, a biotech venture studio focused on accelerating innovations that can lead to cures for patients. He was previously the founding CEO at DeckTherapeutics (acute omega-3 therapeutics), co-invented the technology and led Mirakel Technologies (developing dynamic electrochemistry-based applications in medicine and cosmetics), and co-founded Scientific Innovations, a venture studio between Singapore and New York (spun-out companies in the areas of digital health/preventive cardiology, prescribed nutrition). Suman has an MD in clinical medicine, MSc in human genetics, and did his PhD on personalizing chemotherapy regimens in breast cancer patients based on their genetic constitution. He attended MIT as a Sloan Fellow, receiving his MBA with a focus on innovation and global leadership.
Auriane Gamelin, Co-Founder and COO, OncoXome
Auriane Gamelin, MBA Entrepreneurship and Finances, Co-Founder and COO, has held operational roles at Fortune 500 companies for over a decade, starting with Xerox France. After completing her MBA, Ms. Gamelin managed the production of TV shows at Walt Disney Animation Studios and later Warner Brothers. Later, she worked at the fast-growing Snap Inc., where she vastly increased the platform’s international markets after hiring her own team and implementing proper strategies. With this operational experience, Ms. Gamelin decided to fully commit to advancing cancer research and started OncoXome with her father, Erick. She also earned certifications in drug development processes from UC-Berkeley and completed a training program in clinical investigations at the FDA headquarters.
Crystal Nyitray, PhD, CEO and Founder, Encellin
Crystal Nyitray, PhD, is the CEO and Founder of Encellin, a company building a cell-based pipeline to treat high unmet clinical needs. Encellin’s technology combines a proprietary cell encapsulation technology with functional cell therapy to deliver safe and dynamic therapies. Dr Nyitray is deeply passionate about developing freedom enabling therapies to help patients with high unmet clinical needs. Prior to Encellin, Dr Nyitray was responsible for sourcing and evaluating diabetes opportunities for Sanofi for strategic alignment within their diabetes division. After which she worked at UCSF-QB3, where she developed a keen understanding of the necessary steps to commercialize healthcare technologies. In her role at QB3. Dr. Nyitray managed a portfolio of over 300 startup companies, and mentored over 40 companies. Dr Nyitray’s completed her PhD at UCSF, in the lab of Dr Tejal Desai. Her research has resulted in multiple publications, invited talks, awards and is the foundational technology of Encellin’s living medicines pipeline.